FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Novel Neurology Drugs in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BL-001

            Therapeutic Area: Neurology

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: ALS Association

            Deal Size: $0.5 million Upfront Cash: Undisclosed

            Deal Type: Funding March 17, 2020

            Details:

            Bloom is leveraging its GOLD platform in combination with strong pre-clinical data to advance a new generation of therapeutics aimed at managing gut microbiota.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Topiramate

            Therapeutic Area: Neurology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 17, 2020

            Details:

            Results demonstrated bioequivalence to the currently approved oral solid formulation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anti-tau monoclonal antibody

            Therapeutic Area: Neurology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Aprinoia Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 16, 2020

            Details:

            The candidate was selected from APRINOIA’s proprietary antibody platform to target specific pathological tau aggregates with novel conformation-dependent epitopes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Servier

            Deal Size: $363.3 million Upfront Cash: $3.3 million

            Deal Type: Partnership February 17, 2020

            Details:

            The partnership drew on the complementary expertise of Servier and Oncodesign in the fields of neurodegenerative diseases and macrocyclic kinase inhibitors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabinoids

            Therapeutic Area: Neurology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Solarvest BioEnergy

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 04, 2020

            Details:

            Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares to Solarvest, which will enable Solarvest to fund the CBD Research Project.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omnitram

            Therapeutic Area: Neurology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 04, 2020

            Details:

            Findings could put desmetramadol in pivotal high-value position for safer opioid prescribing.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Neural stem cells

            Therapeutic Area: Neurology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: University of California, Irvine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 03, 2020

            Details:

            Program will utilize AgeX’s proprietary PureStem® cell derivation and manufacturing technology platform. Goal of developing cellular therapies for Huntington’s disease other neurological conditions.

            Parkinson’s Foundation

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabinoids

            Therapeutic Area: Neurology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Zelira Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 28, 2020

            Details:

            Zelira Therapeutics is assisting Parkinson’s Foundation in the development of a survey to understand the current use and perceived benefits of medical cannabis among people with PD.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Verdiperstat

            Therapeutic Area: Neurology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 22, 2020

            Details:

            This will be the second potentially registrational trial of verdiperstat in neurodegenerative disorders.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GNE-0723

            Therapeutic Area: Neurology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 14, 2020

            Details:

            The small molecule increases the activity of a subset of neurotransmitter (NMDA) receptors that are found at synapses, the connection points between neurons.

            PharmaCompass